Researcher brief comment: The company is mainly engaged in innovative research, development, production and sales of biomedicine, and is a biomedical innovation enterprise with intellectual property as the core. The company continues to launch new technologies and products in the fields of genetically engineered drugs, photodynamic drugs, and nanopharmaceuticals, etc., forming a clear competitive advantage, and it is expected that new drugs will be launched on the market one after another in the future. The company officially switched from GEM to Main Board trading at 9 o'clock on December 16, 2013, and the code was changed from 8231.HK to 1349.HK. We believe this is an important milestone in the company's development. The company hopes to become a benchmark enterprise in the photopower field and maintain a good growth trend in the future. Investors are advised to keep a close eye on it.